Clinical Trials on RAI in Poland

Total 17 results

Military Institute of Medicine, Poland

Completed

Monitoring of Adequate Course of General Anesthesia (MoDA)

Monitoring of Depth of Anesthesia | AAI Index

Poland
Oregon Health and Science University

Completed

Dosimeter Location in Pain Physicians

RAD

United States
University Hospital in Krakow

Completed

Impact of Teeth Brushing in Ventilated COVID-19 Patients.

Microbial Colonization | Dysbiosis | COVID-19 Respiratory Infection | HAI | VAP - Ventilator Associated Pneumonia

Poland
AbbVie

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ABBV-3373 in Participants With Moderate to Severe Rheumatoid Arthritis (RA)

Rheumatoid Arthritis (RA)

United States, Germany, Hungary, Israel, Netherlands, Poland, Puerto Rico
Astellas Pharma Global Development, Inc.

Completed

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ASP5094 Following Multiple Intravenous Doses in Subjects With Rheumatoid Arthritis on Methotrexate

Rheumatoid Arthritis (RA)

United States, Poland
Amgen

Terminated

Safety and Efficacy of Efavaleukin Alfa in Subjects With Active Rheumatoid Arthritis

Rheumatoid Arthritis RA

United States, Poland, Germany, Bulgaria, Spain
Amgen

Recruiting

Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

Advanced Solid Tumors | Kirsten Rat Sarcoma (KRAS) pG12C Mutation

United States, Italy, Taiwan, Spain, United Kingdom, Australia, Austria, Germany, Belgium, Japan, Netherlands, Korea, Republic of, Canada
Pfizer
Bristol-Myers Squibb

Completed

Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation

MSS | RAS-mutant Colorectal Cancer

United States, Spain, Belgium, United Kingdom, Netherlands
Sanofi
Regeneron Pharmaceuticals

Completed

To Evaluate Sarilumab - SAR153191 (REGN88) - Auto-injector Device In Patients With Rheumatoid Arthritis (SARIL-RA-EASY)

RA

United States, Chile, Mexico, Poland, Russian Federation, South Africa
AbbVie

Completed

A Study to Investigate the Safety and Efficacy of ABBV-105 Alone or in Combination With Upadacitinib (ABBV-599 Combination) in Participants With Active Rheumatoid Arthritis

Rheumatoid Arthritis (RA)

United States, Belgium, Canada, Czechia, Hungary, Poland, Puerto Rico, Spain, United Kingdom
Dainippon Sumitomo Pharma Europe LTd.

Terminated

Assessment of Safety, Pharmacokinetics and Efficacy in a Combination Treatment With SMP-114

Rheumatoid Arthritis (RA)

Czech Republic, Germany, Poland, United Kingdom, Hungary, Netherlands
AbbVie

Terminated

A Study in Rheumatoid Arthritis Patients Who Have Completed a Preceding Study With ABBV-105 Given Alone or in Combination With Upadacitinib

Rheumatoid Arthritis (RA)

Belgium, Canada, Czechia, Hungary, Poland, Spain, United Kingdom
Day One Biopharmaceuticals, Inc.

Recruiting

Tovorafenib (DAY101) Monotherapy or in Combination With Other Therapies for Patients With Melanoma and Other Solid Tumors

Melanoma | Colorectal Cancer | Solid Tumor | Non Small Cell Lung Cancer | Bladder Cancer | Thyroid Cancer, Papillary | Pilocytic Astrocytoma | Bladder Urothelial Carcinoma | Non-Small Cell Adenocarcinoma | MEK Mutation | RAS Mutation | Pancreatic Acinar Carcinoma | RAF Mutation | CRAF Gene Amplification | RAF1 Gene Amplification and other conditions

United States, Canada, Korea, Republic of, Spain, Australia, Belgium, France
AbbVie

Terminated

Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA)

Rheumatoid Arthritis (RA)

United States, Australia, Canada, Czechia, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, Republic of, Netherlands, New Zealand, Poland, Puerto Rico, Russian Federation, Slovakia, Spain, Taiwan, Turkey, Ukraine
AbbVie

Completed

A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs

Rheumatoid Arthritis (RA)

United States, Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, Czechia, Germany, Greece, Hungary, Ireland, Israel, Italy, Korea, Republic of, Latvia, Mexico, Netherlands, New Zealand, Poland, Portugal, Puerto Rico, Romania, Russian... and more
Bristol-Myers Squibb

Completed

Methotrexate-Inadequate Response Study

Rheumatoid Arthritis (RA)

Italy, Korea, Republic of, Mexico, Taiwan, United States, Chile, France, Poland, United Kingdom, Argentina, Belgium, Ireland, Germany, Netherlands, Canada, India, Russian Federation, Turkey, Australia, South Africa, Brazil, Hungary, Per... and more
AbbVie (prior sponsor, Abbott)

Completed

EValuation of HumIRA® in Patients With Active Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis in EASTern European Countries (EviraEAST)

Ankylosing Spondylitis (AS) | Psoriatic Arthritis (PsA | Rheumatoid Arthritis (RA

Croatia, Hungary, Israel, Poland, Romania, Slovakia, Ukraine

Clinical Trials on RAI in Poland

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Moldova

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations